Form 4: MapLight Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Christopher A. Kroeger, Chief Executive Officer and a Director of MapLight Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.
Summary
- Grant/award: acquired 23,145 Voting Common Stock on August 17, 2026; holds 1,269,600 after (Direct).
- Grant/award: acquired 93,955 Employee Stock Option (right to buy) on August 17, 2026; holds 93,955 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Christopher A. Kroeger — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Grant/award | Voting Common Stock | 23,145 | — | — | 1,269,600 |
| 2026-08-17 | Grant/award | Employee Stock Option (right to buy) | 93,955 | — | — | 93,955 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Grant/award (23,145 shares) |
| 2026-08-17 | Grant/award (93,955 shares) |
Keywords
insider transaction, Form 4, MPLT, MapLight Therapeutics, Inc., neutral, Christopher A. Kroeger
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.